Member Feature: Novo Nordisk

Novo Nordisk is a founding member of ScanBalt and supports the Novo Nordisk – ScanBalt PhD/Scholarship programme.

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 20,250 full-time employees in 78 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London.

– I wish we could solve the problem of diabetes in my lifetime – even if that sounds strange as this is where we make our living. But if it can be done, we must be the ones to do it.
With all our technological progress it must surely be possible to cure diabetes, and with all our knowledge and expertise it would be a crime if we did not try to find the solution. After all, being there for our patients is our express goal, and we know that their greatest wish is good health. So we must – and indeed want to – do our utmost to solve the riddle and then we’ll have to find another way of making our living.

Lars Rebien Sørensen, President and CEO, Novo Nordisk A/S

Read more at http://www.novonordisk.com

Read more about the Novo- Nordisk – ScanBalt PhD/Scholarship programme here.

Read more about membership here.